GlassScriptPhysician profile
Colette C Parker
NPI 1053357749
$8,662.64
in general payments reported to CMS, 2019-2025
20 companies · $6,209 in 2025
The $6,209 reported for 2025 was more than what 87% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $780 · 2020: $82.37 · 2021: $231 · 2022: $779 · 2023: $264 · 2024: $318 · 2025: $6,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,500 · Food and Beverage: $1,881 · Travel and Lodging: $1,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,500.00 |
| Food and Beverage | $1,880.88 |
| Travel and Lodging | $1,410.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $4,256.98 | 2023-2025 | Daybue |
| Livanova USA, INC. | $1,610.66 | 2019-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $1,103.76 | 2019-2025 | Fintepla |
| Jazz Pharmaceuticals INC. | $631.86 | 2022-2025 | |
| Immedica Pharma US, INC. | $253.83 | 2022-2024 | |
| Eisai INC. | $208.98 | 2019-2021 | |
| Greenwich Biosciences, INC. | $100.85 | 2019-2020 | |
| Sk Life Science, INC. | $94.62 | 2024-2025 | |
| Piramal Critical Care | $68.63 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $59.83 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $50.38 | 2025 | |
| Saol Therapeutics INC. | $43.60 | 2019-2020 | |
| Ptc Therapeutics, INC. | $38.78 | 2019-2022 | |
| Catalyst Pharmaceuticals, INC. | $27.22 | 2023 | Fycompa |
| Neurelis, INC. | $24.47 | 2024 | Valtoco |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $24.27 | 2019 | |
| Orchard Therapeutics North America | $23.24 | 2025 | Lenmeldy |
| Genzyme Corporation | $16.21 | 2022 | |
| Ns Pharma, INC. | $12.48 | 2022 | |
| Novartis Pharmaceuticals Corporation | $11.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colette Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.